While it’s easy to assume only performance horses get stomach ulcers, the reality is that all horses are at risk for equine gastric ulcer syndrome (EGUS).
Research shows more than 60 percent of performance horses, 30 percent of pleasure horses, and between 25-51 percent of foals suffer from gastric ulcers. That’s because horse-related stressors—which can lead to EGUS—are everywhere, from unfamiliar noises and changes in routine to frequent trailering and intense training.
To help veterinarians provide a “gut check” for horse owners on the risk of equine gastric ulcers and how to treat and/or prevent them, Boehringer Ingelheim is providing downloadable educational event toolkits at Gastrogard.com/VetResources.
Two versions of the kit are available, one for veterinarians who offer gastroscopy exams and one for those unable to do so.
The kits include a comprehensive set of materials for hosting an EGUS event for horse owners, from invitations and social posts to posters and handouts.
“The clinical signs of EGUS, including behavioral issues and poor performance, can be so common horse owners often ignore them or attribute to some other issue,” says Hoyt Cheramie, DVM, MS, DACVS, Senior Equine Professional Service Veterinarian for Boehringer Ingelheim. “Educating horse owners on the signs, as well as the importance of engaging the veterinarian, can help support the proper diagnosis, treatment and ultimately prevention of stomach ulcers.”
For veterinarians with a gastroscope, the kit includes resources for hosting a gastroscopy event or demonstration to teach horse owners about gastric health and encourage attendees to schedule scopings for their own horses.
For those without a gastroscope, materials are available for hosting a general open house or educational dinner without the live scoping piece.
“It’s important to train horse owners on the importance of getting a proper diagnosis so that appropriate treatment can begin quickly, such as a recommended course of Gastrogard (omeprazole),” Cheramie says. “In addition, increased awareness of EGUS can empower veterinarians to provide environmental, management and nutritional recommendations to help prevent future stomach ulcers.”
GASTROGARD IMPORTANT SAFETY INFORMATION The safety of GASTROGARD paste has not been determined in pregnant or lactating mares. For use in horses and foals 4 weeks of age and older. Keep this and all drugs out of the reach of children. In case of ingestion, contact a physician. Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
About the Equine Business of Boehringer Ingelheim
As the global leader in equine health, Boehringer Ingelheim’s main goal is to improve equine patients’ health and quality of life. We are dedicated to providing the latest product technology for the treatment and prevention of disease in horses. Learn more about our product portfolio and what we can offer the veterinary community by visiting https://www.bi-vetmedica.com/species/equine.html.
About Boehringer Ingelheim Animal Health USA, Inc.
Boehringer Ingelheim is the second-largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
GASTROGARD is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0054-2019
1. Mitchell, R.D. Prevalence of gastric ulcers in hunter/jumper and dressage horses evaluated for poor performance. Association for Equine Sports Medicine, September 2001.
2. Sykes, B.W., et al. ECEIM Consensus Statement – EGUS in Adult Horses. J Vet Intern Med 2015; 29: 1288-1299.
3. Wilson, J.H. Gastric and duodenal ulcers in foals: a retrospective study, in Proceedings, 2nd Equine Colic Res Symp. 1986;126-129.
4. Murray, M.J.; Hart, J.; Parker, G.A. Equine gastric ulcer syndrome: endoscopic survey of asymptomatic foals. AAEP Proceedings. 1987;33:769-776.